Vax-Immune Diagnostics Takes Innovative Women's Health Diagnostic Device to European Markets to Improve Maternal Group B Strep Testing Processes
Share this article HOUSTON, Feb. 17, 2021 /PRNewswire/ -- Vax-Immune Diagnostics announces today it has received CE Mark approval for its first-in-class medical device, LabReady® GBS. LabReadys Group B Strep product is the first in Vax-Immune Diagnostics lineup of womens health solutions that helps avoid life-threatening complications and expensive consequences for mothers and their babies. With CE Mark approval, LabReady is now available to European physicians, patients, and hospital syst...
United States Eileen Litwin Leonarde Weisman Labready Groupb Strep Vax Immune Diagnostics Groupb Strep
Source: prnewswire.com